Projects per year
Personal profile
Interests
Nanomedicine, Antibodies, Antibody-Drug Conjugates (ADCs), cathepsin proteases, cancer, inflammation, infection
Research Statement
Professor Chris Scott is Director of the Patrick G Johnston Centre for Cancer Research. Following a primary degree in Biochemistry he undertook a PhD and post doctoral training at Queen’s in molecular enzymology. In 2001, Chris was one of the founding members of QUB spinout company Fusion Antibodies Ltd., before returning to Queen’s in 2003 to take up an academic position. Chris is internationally renowned for his work in development of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions. Work in his laboratory is funded by agencies such as Medical Research Council, US-Ireland, and various industrial sources such as AstraZeneca and Immunocore. He also held a Royal Society Industrial Fellowship with GSK from 2012-15, and won the Vice Chancellor’s Prize for Innovation in 2015 with his group’s work on developing a novel nanomedicine for the treatment of sepsis and other inflammatory conditions. Chris is a member of the Medical Research Council Developmental Pathway Funding Scheme Panel.
Fingerprint
- 9 Similar Profiles
Network
Projects
-
R1135CNR: Exploiting the cancer epigenome to develop a common cancer vaccine
McDade, S., Jafarnejad, S. M. & Scott, C.
10/01/2020 → …
Project: Research
-
-
-
R1846CNR: Development of intracellular VNARs as novel tools to dissect intracellular biological processes
20/12/2017 → …
Project: Research
Research output
-
Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature
Leach, A., Smyth, P., Ferguson, L., Steven, J., Greene, M. K., Branco, C. M., McCann, A. P., Porter, A., Barelle, C. J. & Scott, C. J., 21 Jul 2020, In: Nanoscale. 12, 27, p. 14751-14763 13 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)19 Downloads (Pure) -
A revised model of TRAIL-R2 DISC assembly explains how FLIP(L) can inhibit or promote apoptosis
Humphreys, L. M., Fox, J. P., Higgins, C. A., Majkut, J., Sessler, T., McLaughlin, K., McCann, C., Roberts, J. Z., Crawford, N. T., McDade, S. S., Scott, C. J., Harrison, T. & Longley, D. B., 31 Jan 2020, In: EMBO Reports. 21, e49254.Research output: Contribution to journal › Article › peer-review
Open AccessFile7 Citations (Scopus)79 Downloads (Pure) -
Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer
Sereesongsaeng, N., McDowell, S. H., Burrows, J. F., Scott, C. J. & Burden, R. E., 09 Dec 2020, In: Breast Cancer Research. 22, 1, p. 139Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
Greene, M. K., Chen, T., Robinson, E., Straubinger, N. L., Minx, C., Chan, D. K. W., Wang, J., Burrows, J. F., Van Schaeybroeck, S., Baker, J. R., Caddick, S., Longley, D. B., Mager, D. E., Straubinger, R. M., Chudasama, V. & Scott, C. J., 11 Sep 2020, In: British Journal of Cancer.Research output: Contribution to journal › Article › peer-review
-
DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models
Johnston, M., Nicoll, J., Redmond, K., Smyth, P., Greene, M., McDaid, W., Crawford, N., Stott, K., Fox, J., Longley, D. & Scott, C., 10 Aug 2020, In: Journal of Controlled Release. 324, p. 610-619 10 p.Research output: Contribution to journal › Article › peer-review
Activities
-
KTP/ Causeway Sensors Ltd - S2410CNR
Christopher Scott (Member) & James Burrows (Member)
01 Apr 2017 → 31 Mar 2020Activity: Consultancy types › KTP & Consultancy in kind
-
British Society of Nanomedicine
Jonathan Coulter (Member of the organising committee) & Christopher Scott (Organiser)
10 Aug 2017 → 11 Aug 2017Activity: Participating in or organising an event types › Participation in conference